Longeveron (LGVN) Completes Enrollment of Pivotal Phase 2b Trial of Laromestrocel
Go back to Longeveron (LGVN) Completes Enrollment of Pivotal Phase 2b Trial of Laromestrocel| LOGICVISION (NASDAQ: LGVN) | Delayed: 0.69 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.69 | 52 Week High | $1.62 | |||
| Open | $0.69 | 52 Week Low | $0.35 | |||
| Day High | $0.69 | P/E | N/A | |||
| Day Low | $0.69 | EPS | $-0.17 | |||
| Volume | 3,042 | |||||
| (NASDAQ: LGVNR) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $ | |||
| Open | $2.45 | 52 Week Low | $ | |||
| Day High | $0.00 | P/E | N/A | |||
| Day Low | $0.00 | EPS | $ | |||
| Volume | 23,525,480 | |||||
